Quintiles and IMS Health
today announced a global strategic alliance that will advance the way
biopharmaceutical companies generate real-world evidence (RWE) and apply
critical insights to drive late-stage clinical research. The companies say, the
move will improve clinical trial design, recruitment and execution in the
$100-billion biopharma product development market by combining IMS Health’s
global information solutions with Quintiles’ product development skills.